Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control.

Philis-Tsimikas A

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.

Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjøth TV, Rasmussen S, Garber AJ

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.

Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC, ACCORD Study Group

Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).

Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).

Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C, NN1250-3579 (BEGIN Once Long) Trial Investigators

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J, Liraglutide-Detemir Study Group

Precision, accuracy, and user acceptance of the OneTouch SelectSimple blood glucose monitoring system.

Philis-Tsimikas A, Chang A, Miller L

Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce promotora randomized trial.

Philis-Tsimikas A, Fortmann A, Lleva-Ocana L, Walker C, Gallo LC

Glycemic control among Latinos with type 2 diabetes: the role of social-environmental support resources.

Fortmann AL, Gallo LC, Philis-Tsimikas A

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B, LEAD-3 (Mono) Study Group